Vice President for Research

Information regarding CDMRP funding for FY25 can be found in the following press release: https://cdmrp.health.mil/pubs/press/2025/FY25_Appropriations

The FY25 funded programs are as follows:

• Amyotrophic Lateral Sclerosis Research Program - $40.0 million
• Breast Cancer Research Program - $130.0 million
• Duchenne Muscular Dystrophy Research Program - $12.5 million
• Melanoma Research Program - $40.0 million
• Military Burn Research Program - $10.0 million
• Ovarian Cancer Research Program - $15.0 million
• Peer Reviewed Alzheimer's Research Program - $15.0 million
• Peer Reviewed Cancer Research Program (18 topics) - $130.0 million
• Peer Reviewed Medical Research Program (42 topics) - $150.0 million
• Prostate Cancer Research Program - $75 million
• Rare Cancers Research Program - $17.5 million
• Toxic Exposures Research Program - $15.0 million

Pre-announcements and funding opportunity announcements will be forthcoming. Pre-announcements will provide a brief overview of anticipated funding mechanisms within each program. Funding opportunity announcements will include detailed descriptions of award mechanism intent, evaluation criteria, submission requirements, and deadlines. Each funding opportunity announcement will be posted on CDMRP https://cdmrp.health.mil, Grants.gov https://www.grants.gov, and eBRAP https://eBRAP.org.

For email notification when pre-announcements and funding opportunity announcements are released, subscribe to program-specific news and updates HERE (under "Email Subscriptions" on the eBRAP homepage.)